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During the pandemic healthcare faced great pressure on the availability of protective
equipment. This paper describes the entire novel innovative process of design optimisa-
tion, production and deployment of face-visors to NHS frontline workers during SARS-CoV-
2 pandemic. The described innovative journey spans collaboration between clinicians and
academic colleagues for design to the implementation with industry partners of a face-
visor for use in a healthcare setting. It identifies the enablers and barriers to develop-
ment along with the strategies employed to produce a certified reusable, adjustable, high
volume and locally produced face-visor. The article also explores aspects of value, scal-
ability, spread and sustainability all of which are essential features of innovation.
© 2021 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and
Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.Introduction
In the UK there have been 61,648 deaths and 1.34 million
confirmed cases from SARS-Cov-2 up until 19th November
2020.1 During this acute period numerous innovations have
been developed in the NHS to meet the demands of the dis-
ease on the healthcare system. Given the critical timescale of
COVID-19, the need for the rapid development of local per-
sonal protective equipment (PPE) solutions to address these
shortages has become apparent.2
The development process of the full-length face-visor as a
product, but also the collaborative development of it with
engineers, academics and industry is itself an innovation
because it fulfils an unmet clinical need through methods not
commonly used in healthcare.3,4
The innovation process within the NHS is very different to
that in industry. Healthcare delivery is a highly complex sys-
tem as demonstrated during this pandemic where processes
and standards have constantly evolved in relation to safety
and cross infection control.5. Din).
ovation in the time of SA
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Development of policy
The first recorded eye glasses date back the 15th Century6; in
modern history, the first patent awarded for eye protection
was in 1880.7
In modern times, policy and legislation has been in place
for a number of years as eye protection has been part of
routine PPE involving aerosol generating procedures. Under
the Health and Safety at Work Act 1974,8 supported by the
Management of Health and Safety at Work Regulations 19999
and COSHH Regulations 2002,10 employers have a legal re-
sponsibility to provide appropriate PPE for healthcare workers
including eye and face protection against splashes and
aerosol.11
This can be achieved either by a surgical mask with an
integrated visor, a full face-visor, polycarbonate safety spec-
tacles or equivalent; regular corrective spectacles are not
considered adequate eye protection.11 During SARS-CoV-2 the
need for a full-face shield or visor requirement has been un-
equivocal. Face visors need to meet specific standards (BSI ENRS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
arity number SC005317) and Royal College of Surgeons in Ireland.
Fig. 1 e Image showing face coverage with short visor (left) and longer visors (right). The short visor fails to extend to cover
the whole forehead nor the neck. The side extension across to the ears is less.
t h e s u r g e on x x x ( x x x x ) x x x2166:2001) prior to deployment.12 These requirements were
distilled by the British Standards Institute (BSI) during the
COVID-19 response allowing a wider range of products to be
used during this period.Unmet clinical need
The SARS-CoV family are transmissible by droplets, aerosol
and splatter through saliva and bodily fluids. For healthcare
clinicians who deal with the airway, there is material risk for
inoculation through saliva due to high viral loads detected in
saliva samples.13 Inoculation has been shown via mucous
membranes of the respiratory tract with the infectivity
through the ocular membranes an additional risk.14,15 The
chance of infectivity increases due to the uncertainty intro-
duced through asymptomatic carriers16; potentially giving
clinicians a false sense of security of a patient not being
infective and being treatedwith less robust protocols. There is
evidence from previous regression analysis of SARS trans-
mission, illustrating a statistically increased risk of inocula-
tion of SARS-CoV in healthcare staff who did not wear suitable
eye-protection.17
The acronym PPE has become part of the lexicon for all
clinicians from the start of this pandemic. The UK gov-
ernment identified a shortage of certain items of PPE pri-
marily due to massive global demand; as such reliance on
overseas manufacturing for supply of this has been laid
bare.18e20
Existing visors used by UK healthcare workers including
dentists, are usually short visors designed to retrofit onto
glasses or onto a plastic frame more as eye protection onlyPlease cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/(Fig. 1A and B). Previously full-face visors have not gained
much traction in frontline healthcare with visors failing to
meet some desirable design properties:
1. Length of visor should cover the whole neck and forehead
2. Be height adjustable for various procedures and stature,
and
3. For sustainability be designed in away for easy disinfection
and re-use.
The aim for this project was to identify and implement
changes to improve the face-visor.Innovation process
The innovative process for the development of this visor can
be classed as a radical change in process, by changing the
method of production, procurement and distribution of an
existing product category.4,21 Being an innovation born out of
constraint, the process shown is a simple (low cost), social
(community driven), clean (efficient use of existing resources)
and lean (elimination of supply chain waste) that has helped
meet the clinical need at the frontline.22
The evolution of the actual soft aspect of innovation (visor
design) has progressed through six iterations of 3D printed
and four injection moulded designs. The iterations are a
consequence of multiple factors including:
1. Engineering feedback
2. Clinical feedback from frontline staff, and
3. BSI standards and policy implementations.RS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
t h e s u r g e on x x x ( x x x x ) x x x 3In the United Kingdom a 17-year lag is described between
the development and research of an innovative idea and the
translation into adoption of that idea.23 Fig. 2 outlines the
innovative progression in relation to key national and inter-
national events for the COVID-19 response.
This innovative journey occurring in countries ahead of the
UKs pandemic had been reviewed in relation to face-visors.Fig. 2 e Timeline of 3D printed (yellow) and injection moulded (o
pandemic including PPE related events (black). Green superimp
Please cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/One of the more prominent face-visor designs proliferating
internationally was by Josef Prusa™ in March 2020.24
Compared to the short face-visors, its improvements include
visor length (below the chin) and crucially the modified
Prusa™ design allowed higher volume, local 3D printing.
There are however some limitations to this design specifically
for dental use; the visor height is insufficient not covering therange) visor production along with key developments in the
osed timeline shows the ramping up of visor production.
RS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
t h e s u r g e on x x x ( x x x x ) x x x4forehead to the trichion and the lack of height adjustability for
variability of procedures.Enablers and barriers25
The enablers and their relationship within the process in
developing this innovation (Fig. 3) can be broadly categorised
as:
1. Clinical healthcare staff
2. Charities and academic grants
3. Academic (non-healthcare) colleagues
4. Industry partners, and
5. Volunteers.
The barriers came from:
1. Lack of technical knowledge on product design
2. Understanding of BSI certification for CE markingFig. 3 e Stakeholders involved this innovative visor projec
Please cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/3. Agreement for infection control clearance for
decontamination
4. National and local policy on PPE
5. Distribution logistics
6. Financial restraints and challenges, and
7. Sustainability.
The lack of economic potential promised by an innovative
idea is the reason they are often not pursued. The economic
value in clinical innovations can be determined by the quality
and cost:
Value¼ Quality ðOutcomes; safety and experienceÞ
Cost ðOver time and across the healthcare systemÞ
The project ensured that the value proposition from the
product would incorporate quality and ensure that the
reusable nature allowed a more cost-effective option; how-
ever, a formal cost-analysis was not completed for this
project due to the urgency and speed at which this devel-
opment occurred. Funding was made more readily availablet including the relationship with the production team.
RS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
t h e s u r g e on x x x ( x x x x ) x x x 5during the pandemic through rapid funding calls allowing
this project to progress with less financial concern. In addi-
tion, the call for expert input through industrial and aca-
demic partners was often provided at no cost. Additional
financial support through in-kind contributions to the proj-
ect, including cost-free tooling for injection moulding
allowed allocation of funds to necessary areas such as British
Standards Institute certification. This in-kind contribution
would not allow for a conventional cost-analysis to be
representative of real-world cost which would normally take
into account other factors in addition to production costs
such as employee costs, workspace and equipment
maintenance.
Fundamentally the science and finance are not the prob-
lem; it's the skill mix and socio-political issues which are the
real challenge.25 Dentists, who are the originators of this
innovation are not generally natural product designers but
adopters of innovation.Timeline
Scaling up production to meet demand and reduce cost but
maintaining or improving the quality was crucial. In this
instance the 3D printed production of visor frames started
four days after the first prototype being finalised on the 13
March 2020. The production delivery of mass-produced 3D
printed visors took seven days from final concept approval.
The injection moulded design took 21 days from approval to
delivery. From the first 3D printed prototype it took just over
onemonth to reach 100 visors; another two weeks to 1000 and
only a further one week until 10,000 units (Fig. 2). This expo-
nential increase in production was the result of multidisci-
plinary innovation, leading to both a product and a hybrid
‘production and logistics’ model that could satisfy the im-
mediate need for the face-visors for frontline staff working in
the highest risk environments such as Critical Care Units and
Emergency Departments whilst eventually reaching sufficient
volumes to equip a large multi-site NHS Trust.
The most common 3D printing method used was Fused
Deposition Modelling (FDM); such printers create flat plastic
shapes one on top of one another which build up into full 3D
objects. Amore advanced printing process, Stereolithographic
(SLA), uses a laser to cure liquid resin in the same 2D shapes,
which are again layered to build up an object; this type of
printing was also utilised during production.
3D printers have become commonplace in schools, uni-
versities and even people's homes, as well as finding a niche in
dentistry among several areas of healthcare.26,27 3D printing
carries several benefits over other manufacturing processes
which were relevant to the needs of this project:
1. Low setup time and cost
2. Readily available materials
3. Virtually no material waste, and
4. Minimal operator attention.
The first part of this innovation relied heavily on ‘crowd-
sourced’ 3D printing capacity to iterate visor designs quickly
and start production in volume very early in the project28;Please cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/enabling four days between the first prototype to first 3D
printed delivery. Through various industrial and academic
partners, a network of over 20 home and lab-based 3D printers
were formed, with an additional industrial printing farm
added to this capacity. To ensure the stringent functionality
and quality standards required for the safe and effective de-
livery of the visors to frontline clinicians, this established a
crowd-manufacturing approach embedded in this otherwise
centralised design.12 An online forum was set up to enable
producers to share advice and make joint technical decisions
as well as coordinate deliveries.
Several constraints must be taken into account when
designing a 3D product. Firstly, FDM printers cannot deposit
plastic in thin air or recreate intricate detail, limiting the
shapes reproduced. Material choice is also limited to six
commonly available plastics restricting the mechanical and
chemical properties of parts. This was particularly important
in this case, as the face-visors needed to be resistant to
chemical disinfection. The design of the face-visor was based
on relatively simple geometry replacing small and fragile
hooks seen on similar 3D printed visorswith a larger clamping
mechanism across the entire front rim. Polylactic Acid (PLA)
and Polyethylene Terephthalate Glycol (PET-G) were the ma-
terials of choice due to their slight flexibility and resistance to
the strong sterilisation disinfectants.
Automation is key for large 3D print farms to maintain a
high output. 3D printers traditionally require human input to
off-load printed products prior to next batch printing; how-
ever, this is impractical for very large-scale production. Large
print farms, such as those used by the industrial partners
(batch.works Ltd) in this project used a number of techniques
to accelerate the 3D printing process. Automation systems
included robotic pistons that could remove parts when prints
complete and cameras that compares the print to the 3D
design to check for errors.29 The printer set-up itself was
optimised for speed, with large plastic extruders capable of
depositing material up to 20 times faster than typical ma-
chines. The model design was also reworked to print quickly
by examining the printhead's path and removing any geom-
etry that created time consuming ‘hops’ around the 2D layers.
Whilst the 3D printing network produced batches at its
peak of 1000 visors per week, the team worked with another
industrial partner (Halma PLC and Apollo Fire Detectors Ltd) to
set up high-volume injection moulding tooling to produce
batches of up to 10,000 visors per week. Injection moulding
offered a much faster process, with a single visor produced in
less than 30 s compared to the 20 min taken by the fastest 3D
printers. However, this was subject to a three-week set-up
time with sample batches taking up to a week to be des-
patched for verification; when compared to 3D printers which
started printing as soon as digital design file was finalised
resulting in a superior turn-around rate. A key element of
success of this innovation was the adoption of technologies
combining 3D printing to satisfy urgent need and then injec-
tion moulding to meet the ever-increasing demand longer
term.
Another challenge in supporting a large, loosely connected
network ofmanufacturerswas the variation in specification of
each machine. This led to constraints including smaller build
volumes or lower print resolutions, whilst others offeredRS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
Fig. 4 e Visor design versions: A. Reference design; B. High clearance design; C. Stacked 3D design; D. Colour design; E.
Injection moulding design.
t h e s u r g e on x x x ( x x x x ) x x x6distinct advantages which were leveraged to improve volume
or quality; for example, dissolvable support structures in
multi-material printers. Injection moulding required another
design variant to accommodate restrictions on shapes that
could be moulded. In total, six different versions of the visor
were produced after receiving necessary clinical approval for
production:
1. Reference design, suitable for the majority of desktop FDM
3D printers (Fig. 4A)
2. Low resolution design, with larger text and a more pro-
nounced acetate clamping design suitable for low-
resolution (but very high speed) print farms as described
above
3. High clearance design for very fast chemical (resin)
printers which experience a small amount of expansion
during post processing (Fig. 4B)
4. Stacked design for printers able to print with easily
removable support structures (Fig. 4C)
5. 2 colour design with high-contrast branding and instruc-
tion text for printers able to print in two different plastics
(Fig. 4D), and
6. Injectionmoulding ready designwith break-apart ‘teeth’ to
replace the friction-based clamp, which could not be
moulded (Fig. 4E).
The final stages of production included CE marking certi-
fication through the British Standards Institute (UK). The
processmarked the product asmeeting the high safety, health
and environmental requirements set out by the EU for all
products sold in the European Economic Area for use during
the COVID-19 pandemic11,12; this objectively confirmed the
radical change offered through this innovation met clinical
and regulatory requirements.Spread and communication
Communication and dissemination of information is crucial
to development of any new innovation. Remote development
has boomed with significant increases in the use of remote
working programs such asMicrosoft™ Teams and Slack™.30,31
Changes in working patterns have also been identified people
aremore likely to be flexible in their working day.30 Challenges
of remote working for novice users include a learning curve
which can hinder productivity and speed of communication.31
This dramatic shift towards remote working was adopted
by the stakeholders to collaborate on the project which wouldPlease cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/not have been possible without virtualisation; this primarily
enabled dissemination of information, sharing and approval
of designs.
In addition communication through social media allowed
for the spread of knowledge to the existing online pool of in-
formation.32 The use of social media was not restrained to
marketing purposes but for open innovation creation
including ‘ideation, R&D, and commercialization’.32 This
paradigm shift in the use of social media allowed for the
development of new ideas with important stages in visor
development creatively linking healthcare and university
stakeholders. More importantly the shift from the innovators
being solely involved in the decision-making process is no
longer an acceptable method of designing products. Instead it
was recognised that collective intelligence from ideation to
end-users were a necessity to rapidly develop and redesign
the product allowing the final visor to reflect the unique
clinical and technical specifications required.32Sustainability
Sustainability is essential in the innovative process due to the
finite resources available. There is a rising risk of unsustain-
able behaviours localised in the acute fight against the virus;
examples include the significant rise in single-use plastics in
respirator masks, PPE and medical devices. 85% of all clinical
waste is incinerated and not recycled; in the UK the waste
heat produced from incineration is sometimes reclaimed for
energy.33
A life cycle analysis for any new sustainable idea is a pro-
cess which assesses cost, impact and expected lifetime as
important factors in decisionmaking.34 Specifically during the
design process, functionality and demand are crucial com-
ponents in decisionmaking.35 A negative impact of such rapid
development is the loss of a life-cycle analysis in preference
for meeting the unmet demand.
During the development of the visor, effort was instead
placed simply on eco-efficiency and eco-design.34 The 3D
printed design allowed locality of 3D printers close to the
required sites to achieve huge reductions inmanufacturing and
delivery times; printers with locally available staff to produce
3D visors round the clock was the driving factor to meet the
initial unmet demand. The local mass 3D printing partner
achieved high volume by reducing printing times through
efficient designmodifications; this coupledwith recycled PET-G
and the use of pedal bike delivery service allowed for an overall
eco-friendlier approach to local manufacturing.36,37RS-CoV-2: A collaborative journey between NHS clinicians, engi-
j.surge.2020.12.008
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specification which has dramatically helped the on-going
unmet clinical need; this has allowed for lower pressures on
the production volumes longer term. There is a definite
impact on production resources which can be reduced when
reusable products are used in healthcare.38 There is a growing
trend amongst manufacturers towards producing reusable
PPE products answering the calls by frontline users for exactly
such products.39,40
The financial impact of PPE during this pandemic has risen;
the impact on frontline services can mean curtailment of
care.41,42 The financial sustainability of single use items is not
a solution to this pandemic; reusable items must be made a
priority.Discussion
The collaborative effort of stakeholders allowed for the pro-
ductionof visorswhich to datehave beendistributed toprimary
and secondary care settings including those outside of health-
care with over 15,000 visors delivered from this one team alone.
The final effort has resulted in a certified reusable, adjustable,
high volume and locally produced visor (Figs. 1B and 4AeE).
This project has identified that innovation might be made
easier and faster if computer aided 3D design (CAD) were to be
taught as part of the standard Science, Engineering, Medical
and Dental curriculum. The authors include team members
who qualified in their respective degrees with and without
dedicated CAD teaching as part of the curriculum. Initially, the
project presented an enormous learning curve for the clinical
and technical members of this team to learn basics of termi-
nology, concepts and design skills. The integration of CAD
trained engineers into the team, however, accelerated the
product development process significantly, thus decreasing
the time taken for innovation using user feedback to be
delivered to frontline users. Modern dental practices now
more than ever have 3D printing capacity with the technical
competencies to operate printers; however, they do not carry
the training reserved for mechanical engineers and product
designers to design printable models from scratch. The
innovation described in this article was made possible by
leveraging these skills held by mechanical and robotics engi-
neers, but could have been vastly accelerated if basic CAD
training had been part of training curriculums and available to
the hospital where the innovation originated.
The innovative process of using a semi-automated 3D
printing has shown that scalability and dynamic capacity can
be achieved short periods of time. The authors feel there
should be more automated and scalable production methods
used throughout the medical industry with more
manufacturing capacity devolved locally. This dynamic pro-
cess will allow for much faster ramping up during periods of
acute need and disruption to supply chains due to global,
national or local events.
Parts of the world which do not have access to the facilities
that were available to this team are likely to adapt their inno-
vative processes according to the local resources available. It is
therefore very likely that they would leap frog injection
moulding and hard tooling andmove directly to systemswhichPlease cite this article as: Din AR et al., Innovation in the time of SA
neers, academics and industry, The Surgeon, https://doi.org/10.1016/are more flexible such as 3D printing; this leap frogging has
been seen in the telecoms and communication industries.
In summary innovation in healthcare is not new, however
the way the dental and medical profession can collaborate
with academic and industry partners is not always realised.
The production of this visor through wide collaboration was
not truly the innovation but instead the act of collaboration
for the production of the visor was. The professional ties built
during this challenging period will likely flourish into new
ventures of research and enterprise.Sources of financial support
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